Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical implications of pharmacogenetic variation on the effects of statins.

Drug safety - 1 Jan 2011

Maggo Simran D S, Kennedy Martin A, Clark David W J

Abstract excerpt

The last decade has seen an increase in the trend of HMG-CoA reductase inhibitor (statin) usage in the Western world, which does not come as a surprise noting that the latest American Heart Association heart and stroke statistics indicate an alarming prevalence of 80 million Americans (one in thr...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cardiovascular Diseases
Share to Cytochrome P-450 Enzyme System
Share to CETP gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Variation

Share to Genome-Wide Association Study

Share to Hydroxymethylglutaryl-CoA Reductase Inhibitors

Share to Pharmacogenetics

Share to Polymorphism, Genetic

Source

Identifiers

PMID: 21142270
DOI: 10.2165/11584380-000000000-00000

Genes

CETP

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-21142270-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical implications of pharmacogenetic variation on the effects of statins.PMID 21142270Read ↗

Pharmacogenetics of statins treatment: Efficacy and safetySemantic proximity Read ↗

Genetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic review.Semantic proximity Read ↗

Impact of Pharmacogenetics on Efficacy and Safety of Statin Therapy for DyslipidemiaSemantic proximity Read ↗

Pharmacogenomics, lipid disorders, and treatment options.Semantic proximity Read ↗

The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms.Semantic proximity Read ↗

When the same treatment has different response: The role of pharmacogenomics in statin therapySemantic proximity Read ↗

Pharmacogenomic insights into treatment and management of statin-induced myopathySemantic proximity Read ↗

Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of StatinsSemantic proximity Read ↗

Genetics and personalized medicine--a role in statin therapy?Semantic proximity Read ↗

Pharmacogenetics of Statin-Induced MyotoxicitySemantic proximity Read ↗

The pharmacogenomics of statins.Semantic proximity Read ↗

Pharmacogenetics of HMG-CoA Reductase Inhibitors: Optimizing the Prevention of Coronary Heart DiseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.